<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
23.07.2019 16:59:32

DGAP-PVR: Elanix Biotechnologies AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

DGAP Voting Rights Announcement: Elanix Biotechnologies AG
Elanix Biotechnologies AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

23.07.2019 / 16:59
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Name: Elanix Biotechnologies AG
Street: c/o Frankfurt, Hanauer Landstrasse 291 B (BC GmbH)
Postal code: 60314
City: Frankfurt am Main
Germany
Legal Entity Identifier (LEI): 391200SYNFFL0NPAJK90

2. Reason for notification
  Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
X Other reason:
Termination of the voting right agreement

3. Details of person subject to the notification obligation
Natural person (first name, surname): Dr. Anthony De Buys Roessingh
Date of birth: 22 Sep 1967

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
 

5. Date on which threshold was crossed or reached:
18 Dec 2018

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
Total of both in %
(7.a. + 7.b.)
Total number of voting rights pursuant to Sec. 41 WpHG
New 1.76 % 0 % 1.76 % 8.080.902
Previous notification 19.35 % 0 % 19.35 % /

7. Details on total positions
a. Voting rights attached to shares (Sec. 33, 34 WpHG)
ISIN Absolute In %
  Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
Direct
(Sec. 33 WpHG)
Indirect
(Sec. 34 WpHG)
DE000A0WMJQ4 142592 0 1.76 % 0 %
Total 142592 1.76 %

b.1. Instruments according to Sec. 38 (1) no. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
%
    Total %

b.2. Instruments according to Sec. 38 (1) no. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
%
      Total %

8. Information in relation to the person subject to the notification obligation
X Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.).
  Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least 3% or more) % of voting rights through instruments (if at least 5% or more) Total of both (if at least 5% or more)
 

9. In case of proxy voting according to Sec. 34 para. 3 WpHG
(only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG)

Date of general meeting:
Holding total positions after general meeting (6.) after annual general meeting:
Proportion of voting rights Proportion of instruments Total of both
% % %

10. Other explanatory remarks:
 

Date
16 Jul 2019



(Anzeige)Passende neue Barrier Reverse Convertibles

23.07.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Elanix Biotechnologies AG
c/o Frankfurt, Hanauer Landstrasse 291 B (BC GmbH)
60314 Frankfurt am Main
Germany
Internet: www.elanixbiotechnologies.com

 
End of News DGAP News Service

845533  23.07.2019 

fncls.ssp?fn=show_t_gif&application_id=845533&application_name=news&site_id=smarthouse

Nachrichten zu Elanix Biotechnologies AGmehr Nachrichten